Want to see SE:ATORX full AI Analyst Report?
Top Page
Alligator Bioscience AB
(ATORX)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.02
▼(-46.67% Downside)
Action:Upgraded
Date:10/07/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, and heavy cash burn) and a clearly bearish technical trend (below major moving averages with negative MACD). Valuation adds only limited support because the company is loss-making (negative P/E) and offers no dividend yield.
Positive Factors
Improved Leverage
The sharp improvement in debt-to-equity reduces balance-sheet leverage relative to 2025 and may lower financial strain. This gives Alligator somewhat more flexibility to fund development, negotiate partnerships, or manage future financing needs despite its still-small equity base.
Negative Factors
Minimal and Declining Revenue
Minimal, declining revenue shows that the company has not yet established meaningful commercial scale. That limits internally generated funding for research and clinical programs, leaving future progress dependent on partnerships, financing, or eventual successful product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Leverage
The sharp improvement in debt-to-equity reduces balance-sheet leverage relative to 2025 and may lower financial strain. This gives Alligator somewhat more flexibility to fund development, negotiate partnerships, or manage future financing needs despite its still-small equity base.
Read all positive factors
Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr57.45M
Dividend YieldN/A
Average Volume (3M)16.21M
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth-98.81%
EPS Growth80.33%
CountrySE
Employees11
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.06
Shares Outstanding3,568,107,000
10 Day Avg. Volume10,974,517
30 Day Avg. Volume16,206,684
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Alligator Bioscience AB Business Overview & Revenue Model
Company Description
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its ...
How the Company Makes Money
Alligator Bioscience primarily generates or seeks to generate revenue through: (1) out-licensing and partnering its drug candidates and underlying antibody discovery/optimization capabilities to larger pharmaceutical or biotech companies in exchan...
Alligator Bioscience AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 514.00K | 514.00K | 57.77M | 58.11M | 35.70M | 12.94M |
| Gross Profit | -23.37M | -54.82M | 57.77M | 58.11M | -112.03M | -74.04M |
| EBITDA | -83.90M | -121.98M | -165.47M | -237.61M | -180.99M | -130.36M |
| Net Income | -77.69M | -51.35M | -233.89M | -248.59M | -193.40M | -141.74M |
Balance Sheet | ||||||
| Total Assets | 65.11M | 110.60M | 104.34M | 118.45M | 169.58M | 333.20M |
| Cash, Cash Equivalents and Short-Term Investments | 16.61M | 62.20M | 64.31M | 66.12M | 97.31M | 278.15M |
| Total Debt | 29.93M | 43.15M | 43.57M | 16.10M | 24.50M | 9.74M |
| Total Liabilities | 61.79M | 103.74M | 234.93M | 106.59M | 80.53M | 50.93M |
| Stockholders Equity | 3.33M | 6.86M | -130.59M | 11.86M | 89.05M | 282.27M |
Cash Flow | ||||||
| Free Cash Flow | -138.83M | -157.45M | -212.43M | -191.74M | -173.05M | -127.08M |
| Operating Cash Flow | -138.83M | -155.99M | -212.43M | -189.28M | -172.61M | -127.03M |
| Investing Cash Flow | 0.00 | 2.21M | 0.00 | -2.46M | -440.00K | -45.00K |
| Financing Cash Flow | 121.72M | 152.59M | 211.27M | 161.56M | -7.83M | 301.80M |
Alligator Bioscience AB Technical Analysis
Negative
0.03
Price Trends
0.02
Negative
0.07
Negative
0.11
Negative
Market Momentum
>-0.01
Negative
29.76
Positive
7.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ATORX, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 29.76 is Positive, neither overbought nor oversold. The STOCH value of 7.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ATORX.
Alligator Bioscience AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr374.99M | 2.01 | 63.09% | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | kr778.73M | -3.80 | ― | ― | 87.23% | 35.27% | |
48 Neutral | kr184.86M | -7.79 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr371.09M | -3.21 | -18.05% | ― | ― | 15.97% | |
43 Neutral | kr1.52B | -3.07 | -99.58% | ― | -87.22% | -70.29% | |
41 Neutral | kr57.45M | -0.01 | -736.08% | ― | -98.81% | 80.33% |
* General Sector Average
SE:ATORX
Alligator Bioscience AB
0.02
-0.78
-97.99%
SE:BINV
BioInvent International AB
23.05
-4.35
-15.88%
SE:ONCO
Oncopeptides AB
2.04
-3.19
-61.00%
SE:ELIC
Elicera Therapeutics AB
2.77
-4.32
-60.95%
SE:IMMU
Immunicum AB
5.85
-0.06
-1.02%
SE:CANTA
Cantargia AB
1.33
-1.18
-47.10%
Alligator Bioscience AB Corporate Events
Alligator Bioscience Names CFO Johan Giléus as CEO Amid Strategic Refocus on HLX22
Oct 4, 2026
Alligator Bioscience has appointed its current Chief Financial Officer, Johan Giléus, as Chief Executive Officer effective 1 January 2027, succeeding Søren Bregenholt, who will remain in the role until the end of 2026 to ensure a smooth ...
Alligator Bioscience Restructures Fenja Loan With Directed Warrant Issue
Sep 29, 2026
Alligator Bioscience has issued 187,795,097 warrants to Fenja Capital as part of a renegotiated loan arrangement linked to its recently completed rights issue. The new 2026/2031 warrants, replacing an earlier 2025/2030 series, correspond to about ...
Alligator Bioscience’s Rights Issue Heavily Reliant on Guarantees, Triggers Major Dilution
Sep 22, 2026
Alligator Bioscience has reported the final outcome of its rights issue of units, in which only about 17.1 percent of the maximum 3.14 billion units were subscribed by investors, with the remainder largely covered by guarantee commitments. Each un...
Alligator Bioscience’s Rights Issue Undersubscribed, Underwriters Step In
Sep 21, 2026
Alligator Bioscience AB has reported the preliminary outcome of its rights issue of units, launched in July 2026, with subscriptions totaling about 17.1 percent through exercise of unit rights and 16.7 percent without rights. This level of demand ...
Alligator Bioscience Launches SEK 125.6 Million Rights Issue to Refocus Oncology Pipeline
Aug 31, 2026
Alligator Bioscience has published a prospectus for a rights issue of up to 3,140,534,240 units, each comprising two shares and two series of warrants, at a subscription price of SEK 0.04 per unit. The offer, running from 4 to 18 September 2026, c...
Alligator Bioscience Restructures Capital and Launches Major Rights Issue
Aug 26, 2026
Alligator Bioscience’s extraordinary general meeting approved multiple changes to its capital structure, including amendments to the Articles of Association and significant reductions of share capital to cover losses and reallocate funds to ...
Alligator Bioscience exits mitazalimab development to refocus on HLX22 royalties and recapitalisation
Aug 26, 2026
Alligator Bioscience reported a weak second quarter with no significant operational events, continuing to post operating losses and declining cash, while progressing investigator-led studies and data presentations for mitazalimab and highlighting ...
Alligator Bioscience Schedules August Earnings Call Amid Strategic Refocus
Aug 20, 2026
Alligator Bioscience will publish its interim report for the April–June 2026 period related to its HER2-targeting activities on 26 August 2026. On the same day, the company will host an earnings webinar and conference call in English, led by...
Alligator Bioscience Calls Extraordinary Meeting to Restructure Capital and Approve Rights Issue
Jul 23, 2026
Alligator Bioscience AB has called an extraordinary general meeting for 26 August 2026 in Lund, where shareholders will vote on a series of capital and governance measures. The agenda includes amendments to the Articles of Association, multiple de...
Alligator Bioscience Shifts Focus to HLX22 and Launches SEK 125.6 Million Rights Issue
Jul 23, 2026
Alligator Bioscience is discontinuing independent development of its lead drug candidate mitazalimab and shifting strategic focus to the HLX22 project, from which it seeks to preserve future royalty potential. The company also plans to wind down r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.